CorMedix to acquire Heron Therapeutics’ assets in $222.6 million deal
CorMedix Therapeutics announced a definitive agreement to purchase substantially all of Heron Therapeutics’ assets for an upfront value of about $222.6 million, consisting of $145 million in cash and 14,583,333 shares of CorMedix stock. The transaction adds four commercial‑stage products and includes up to $55 million in earn‑out payments and royalties tied to future sales. The companies expect the deal to close in the first quarter of 2027, subject to stockholder and regulatory approvals.
Why it matters
CorMedix says the acquisition will be immediately accretive to earnings and free cash flow and should generate $45 million‑$60 million of annual operating cost synergies by the end of 2027. Citizens analysts highlighted the strategic fit and revenue diversification, reinforcing a positive outlook for CorMedix’s growth.
Key facts
- 1CorMedix will pay $145 million in cash. rttnews.com
- 2CorMedix will issue 14,583,333 shares of its common stock, valued at approximately $77.6 million based on a $5.32 closing price. rttnews.com
- 3The total upfront transaction value is approximately $222.6 million. rttnews.com
- 4Heron may receive up to $55 million in earn‑out payments tied to 2028 ZYNRELEF sales. rttnews.com
- 5CorMedix expects annual operating cost synergies of $45 million‑$60 million by the end of 2027. rttnews.com
- 6Pro forma 2026 revenue is estimated at $465 million‑$490 million. rttnews.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.